Gapping up
In reaction to strong earnings/guidance:
- ABCB +7.9%, SAP +2.8% (also intends spin-off of Qualtrics) RPM +1.7%, AVY +1.3%, ACI +0.9%, VLRS +0.6%, LECO +0.6%
Select metals/mining stocks trading higher:
- AUY +8.1%, SLV +6.5%, GDX +4.2%, GOLD +4%, NEM +3.1%, GLD +2%
Other news:
- TCRR +41.5% (reports RECIST responses with first TC-210 dose tested in advanced mesothelin-expressing solid tumors)
- CNXM +20.4% (CNX Resources (CNX) to acquire remaining public stake in CNX Midstream Partners LP; expected to close in the fourth quarter of 2020)
- MNOV +18.3% (announces SARS-CoV-2 vaccine joint development with BioComo and Mie University Japan)
- AERI +9.4% (reports positive topline results for AR-1105 Phase 2 clinical trial in patients with macular edema due to retinal vein occlusion)
- MRNA +8.4% (receives additional funding to support expanded mRNA-1273 clinical development plan)
- IAG +7.8% (restarts operations at Rosebel Gold Mine)
- GSS +7.1% (to sell Bogoso-Prestea Gold Mine for a purchase price of up to $95 million to Future Global Resources Limited)
- RIGL +6.1% (announces publication of data analysis of TAVALISSE in the British Journal of Haematology)
- BSIG +5.3% (divests affiliates Barrow, Hanley, Mewhinney & Strauss and Copper Rock Capital Partners)
- AMRN +2.5% (presents data from the REDUCE-IT REVASC analysis)
- PCG +1.9% (provides update on equity exit financing over-allotment outcome)
Analyst comments:
- KTB +5.1% (upgraded to Buy from Sell at Goldman)
- TPR +4.5% (upgraded to Buy from Neutral at Goldman)
- BLMN +3.5% (upgraded to Overweight from Neutral at JP Morgan)
- BIIB +2.6% (upgraded to Overweight from Underweight at Morgan Stanley)
- AAL +2% (upgraded to Mkt Perform from Underperform at Raymond James)
- AMZN +1.9% (target raised to $3600 at Telsey Advisory Group)
- PHM +1.8% (upgraded to Overweight from Equal Weight at Wells Fargo)